Coronary Disease Clinical Trial
Official title:
The Impact of Coronary Revascularization on Absolute Myocardial Blood Flow as Assessed by Stress Myocardial Positron Tomography
Regional absolute myocardial blood flow during stress (sMBF) as measured by Positron Emission Tomography (PET) improves post mechanical revascularization provided there is a baseline stress induced perfusion defect. Coronary revascularization performed on regions without a stress induced perfusion defect does not increase the sMBF.
1.0 HYPOTHESIS Regional absolute myocardial blood flow during stress (sMBF) as measured by
Positron Emission Tomography (PET) improves post mechanical revascularization provided there
is a baseline stress induced perfusion defect. Coronary revascularization performed on
regions without a stress induced perfusion defect does not increase the sMBF.
2.0 BACKGROUND Angiographic severity of coronary artery stenosis has historically been the
primary guide to mechanical revascularization and/or medical management of coronary artery
disease. Studies have shown that in patients with stable coronary artery disease (CAD)
percutaneous coronary intervention (PCI) based on angiographic stenosis severity does not
reduce coronary events more than initial medical treatment. In contrast, randomized trials of
PCI report better outcomes when guided by fractional flow reserve (FFR) than when guided by
angiographic severity or when compared to initial medical treatment.
Several potential explanations have been proposed for these conflicting views.
Revascularization procedures may not alter the natural history of multicentric plaque rupture
determined by complex arterial vascular biology. CAD exists diffusely in addition to
segmental stenosis, so that localized mechanical intervention may fail to alter long-term
disease progression or outcome. Additionally, anatomic severity on coronary angiography may
not reflect the physiologic severity that directly determines ischemia, left ventricular
function, and prognosis. Invasive physiologic criteria such as fractional flow reserve (FFR)
can be utilized during invasive angiography to further educate decision making about whether
to perform PCI, however FFR is performed in only 6% of percutaneous coronary interventions
(PCI) in the United States. Consequently, percent stenosis on coronary angiography remains
the main determinant when deciding to proceed with PCI.
It is well established that coronary angiography is frequently unable to adequately
characterize the hemodynamic impact of coronary stenoses. In particular, percent stenosis
does not predict or reliably relate to maximum flow capacity or coronary flow reserve (CFR).
Studies have clearly demonstrated that the anatomical assessment of the hemodynamic
significance of coronary stenoses determined by visual modalities such as coronary
angiography or computed tomography coronary angiography (CTCA) does not correlate well with
the functional assessment of FFR. It is plausible, therefore, that when epicardial vessels
are targeted for revascularization based on percent stenosis, this intervention may not lead
to a significant improvement in myocardial blood flow and in fact could be detrimental.
Myocardial perfusion by positron emission tomography (PET) is a well-established and
validated tool for assessing myocardial perfusion and quantifying absolute myocardial blood
flow. As such, cardiac PET serves as an ideal technology for quantifying changes in flow
after revascularization procedures. Noninvasive myocardial perfusion imaging by positron
emission tomography (PET) combines high spatial resolution (down to secondary or tertiary
coronary branches) with quantitative measures of rest and stress myocardial perfusion in
absolute units to compute absolute coronary flow reserve (CFR). Quantitative myocardial
perfusion by PET has an extensive and technically robust literature, with over 250 papers
including almost 15,000 subjects in the past 25 years.
Furthermore, there is robust data demonstrating prognostic information obtained from stress
myocardial perfusion imaging. However, as counterintuitive and antithetical to modern
practice as it seems, there are no prospective studies demonstrating that mechanical
revascularization on patients with moderate or high risk perfusion scans alters prognosis. In
fact, the ongoing International Study of Comparative Health Effectiveness with Medical and
Invasive Approaches (ISCHEMIA) trial seeks to determine this very question. This study seeks
to determine the regional effects of mechanical revascularization on patients with abnormal
cardiac PET stress tests who were referred to angiography.
3.0 Study Design and Population This is a prospective, single center study from the Ochsner
Medical Center. Adult patients with a stress induced perfusion defect on myocardial PET
scanning who undergo mechanical revascularization will be asked to undergo a subsequent
myocardial PET scan after mechanical revascularization is completed. Socio-demographic data
will also be collected from the participant's electronic medical record.
4.0 Study Procedures All participants eligible for inclusion will be identified and asked to
enroll with a goal of 50 participants. All Individuals will have already had an initial
cardiac PET stress test (PET 1) followed by mechanical revascularization as part of their
routine medical care. Enrolled participants will then be asked to perform a second cardiac
PET stress test (PET 2) within 12 weeks of their revascularization procedure(s). The stress
agents, radiotracer and protocol of PET 1 and PET 2 will be identical and have been described
in previous studies.
5.0 Measurements Baseline absolute coronary flow and CFR will be obtained for each major
coronary artery territory [left anterior descending (LAD), left circumflex (LCx), right
coronary (RCA)] using FDA-approved software. Vessels will be divided into two groups: 1)
those in which the baseline perfusion defect matched the revascularized territory and 2)
those in which there was no baseline defect in the revascularized territory. The change in
pre-vascularization and post-vascularization myocardial blood flow will be compared between
the two groups. Chart review and participant interviews will include patient demographics,
complete medical history, physical examination, laboratory data, 12-lead electrocardiogram
(ECG), Canadian Cardiovascular Society grading of angina pectoris, and procedure reports for
LHC and revascularization procedures.
6.0 Statistical Analysis Paired t-test of the average change in absolute myocardial flow
between the matched and unmatched revascularized territories will be performed using SPSS
software. Participant groups will be compared using Student's t-test (for normally
distributed variable) or Wilcoxon's rank-sum test (for other variables) for continuous
variables and the X2 test or Fisher's exact test for categorical variables. A P value of less
than 0.05 will be considered statistically significant. Multiple logistic regressions will be
used to determine the association between revascularization and sMBF.
7.0 Reporting of Adverse Events or Unanticipated Problems involving Risk to Participants or
Others This study deviates from standard of care in that one additional, not clinically
indicated PET stress test, will be performed soon after mechanical revascularization. Adverse
events or unanticipated problems will be reported to Robert Bober, MD or Fahad Javed, MD at
504-842-2420 and the Internal Review Board as directed by Ochsner Medical Center IRB rules
and regulations. Furthermore, after the first 25 patients have completed PET 2, review of
adverse events and unanticipated problems will be reviewed by a safety monitoring committee
comprised of 3 cardiologists who are not involved with study.
8.0 Radiation Risks Participants who enroll in the study will receive additional ionizing
radiation. The effective dose of a cardiac PET scan is 5mSV or less. This is about 1/10 or
10% of the occupational exposure allowed for a radiation worker. This is also about twice the
annual amount of natural background radiation exposure.
9.0 Study Withdrawal/Discontinuation Participants opting to withdraw from the study will not
have the PET 2 performed.
10.0 Privacy/Confidentiality Issues All hard copies of participant data will be kept securely
the PET department where only PET and research staff has access. All PET workstations are
encrypted and password protected. All participant data and PET results will be de-identified
of individual health information.
11.0 Follow-up and Record Retention This study is estimated to take approximately 9 months to
obtain a total of 50 participants. Hard copies of PET scans are kept securely the PET
department where only PET and research staff has access. The electronic PET data is encrypted
and password protected. Only study personnel will have access to the files.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Completed |
NCT05672862 -
International Post-PCI FFR Extended Registry
|
||
Completed |
NCT04492423 -
VerifyNow® PRUTest® Cardiovascular Population Expected Values On-Drug Study
|
||
Completed |
NCT01205776 -
EXCEL Clinical Trial
|
N/A | |
Recruiting |
NCT01218776 -
International Survey of Acute Coronary Syndromes in Transitional Countries
|
||
Completed |
NCT00046410 -
Comparison of the Risk of Stroke With On- Versus Off-Pump Coronary Artery Bypass Grafting
|
N/A | |
Recruiting |
NCT04390672 -
Multivessel TALENT
|
N/A | |
Completed |
NCT02948517 -
Time Restricted Feeding for Weight Loss and Cardio-protection
|
N/A | |
Completed |
NCT02784873 -
High Intensity Interval Training in UK Cardiac Rehabilitation Programmes
|
N/A | |
Not yet recruiting |
NCT02895009 -
Hemostatic Compression Patterns After Transradial Coronary Intervention
|
N/A | |
Recruiting |
NCT02859480 -
Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI
|
Phase 4 | |
Completed |
NCT02510547 -
Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial
|
Phase 4 | |
Withdrawn |
NCT02418143 -
A Study to Obtain Additional Information on the Use of CorMatrix® CanGaroo ECM® Envelope
|
||
Completed |
NCT02382731 -
Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction
|
N/A | |
Recruiting |
NCT01681381 -
Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization
|
N/A | |
Completed |
NCT02248415 -
Administration of Warm Blood Cardioplegia With or Without Roller Pump
|
N/A | |
Recruiting |
NCT01207167 -
Mediators of Atherosclerosis in South Asians Living in America
|
||
Completed |
NCT02088138 -
Functional Electrical Stimulation in Cardiac Patients
|
N/A | |
Completed |
NCT02173067 -
Anesthesia With Epinephrine in Diabetes Patients is Safe and Effective
|
N/A | |
Completed |
NCT02133807 -
Specific Lp(a) Apheresis for Regression of Coronary and Carotid Atherosclerosis
|
Phase 3 |